tbuckley/cabot-search huggingface dataset:
Role of luteinizing hormone-releasing hormone analog (LHRHa) triptorelin (T) in preserving ovarian function during chemotherapy for early breast cancer patients: Results of a multicenter phase III trial of Gruppo Italiano Mammella (GIM) group.
Authors: L. Del Mastro, L. Boni, A. Michelotti, T. Gamucci, N. Olmeo, M. Giordano, S. Gori, O. Garrone, C. Bighin, M. Venturini
Journal: Journal of Clinical Oncology (2010)

528 Background: To evaluate the role of LHRHa-induced ovarian suppression in preserving the ovarian function (OF) during chemotherapy (CT), a phase III trial was carried out. Methods: Main eligibility criteria: stage I-III premenopausal BC patients (pts), age 18 to 45; hormone receptor (HR) status positive or negative. Arm A: CT alone; arm B: CT + T. T (supplied by Ipsen, Italy) was given every 4 wks during all CT cycles. Allowed CT regimens: CEF or EC (cyclophosphamide, epirubicin, fluorouracil); A (doxorubicin) C; CEF or EC followed by paclitaxel or docetaxel; A or E followed by CMF; CMF. Pts with HR+ tumor received tamoxifen after CT. Primary endpoint: incidence of early menopause (defined by postmenopausal levels of both FSH and estradiol [E2] and no menstrual activity) 1 yr after the end of CT. Study design: multicenter, open-label, randomized, phase III trial. Assuming an incidence of permanent menopause of 60%, for alpha = 0.05 (2-sided) and beta = 0.1 (90% power), 140 pts per arm were needed to detect a 20% absolute reduction in CT+T arm. Results: From Oct 2003 to Jan 2008, 281 pts were randomized: 133 in arm A and 148 in arm B. In both arms median age was 39 and median number of CT cycles was 6. Median cumulative dose of C was 3,840 mg (0-6,930) in arm A and 3,940 mg (0-7,200) in arm B. One yr after CT, early menopause was observed in 43 pts (32.3%; 95% CI 25-41) in arm A and in 20 pts (13.5%; 95% CI 80-91) in arm B (p = 0.0002), with a 19% absolute reduction (95% CI 8-29). Resumption of menstrual activity and/or premenopausal E2 levels was observed in 77 pts (58%; 95% CI 49-66) in arm A and in 114 pts (77%; 95% CI 69-83) in arm B (p = 0.006). Logistic regression analysis confirmed that treatment with T was independently associate with a higher probability of OF preservation (p = 0.001). Conclusions: Temporary ovarian suppression with T during CT is associated with a significant increase in OF preservation in BC pts. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Ipsen
Comorbidities and elevated IL-6 associate with negative outcome in adult-onset asthma
Authors: Pinja Ilmarinen, Leena E. Tuomisto, Onni Niemelä, Joanna Danielsson, Jussi Haanpää, Terhi Kankaanranta, Hannu Kankaanranta
Journal: European Respiratory Journal (2016)

The effect of systemic inflammation and comorbidities on treatment and outcome of adult-onset asthma remains unknown and is the objective of this study. As part of the Seinäjoki Adult Asthma Study (SAAS) with a 12-year follow-up, serum interleukin (IL)-6, high-sensitivity C-reactive protein (hsCRP) and lung function were measured and clinical information on comorbidities and medication collected from 170 patients with adult-onset asthma without chronic obstructive pulmonary disease. At follow-up visit, 54% of the patients had systemic inflammation as indicated by elevated IL-6 or hsCRP, 58% had at least one comorbidity and 30% at least two comorbidities (other than asthma related). Patients with systemic inflammation were treated with higher dose of inhaled corticosteroid (ICS) and they had lower lung function and higher blood neutrophils compared with patients without. Patients having ≥2 comorbidities had lower Asthma Control Test score and this association remained significant in adjusted analysis. Patients with both systemic inflammation and comorbidities showed poorest outcome of asthma. In multivariate regression analysis, high ICS dose was predicted by elevated IL-6, elevated blood neutrophils and eosinophils and poorer lung function at baseline and follow-up. Altogether, in patients with adult-onset asthma, elevated IL-6 was associated with use of high-dose ICS while multi-morbidity was linked to worse symptoms of asthma.
Human Papillomavirus Genotypes Conferring Poor Prognosis in Head and Neck Squamous Cell Carcinoma
Authors: Amanda Psyrri, Theodoros Rampias, Barbara Burtness
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Quality of Care in Profit vs Not-For-Profit Dialysis Centers
Authors: Juan Bosch, Raymond M Hakim, J Michael Lazarus, Charles J McAllister
Journal: JAMA (2003)

To the Editor: In their meta-analysis, Dr Devereaux and colleagues1 concluded that hemodialysis care in private not-for-profit centers was associated with a lower risk of mortality compared with care in private for-profit centers.
Epirubincin Does Not Lower The Risk Of Cardiac Toxicity Than Doxorubicin In Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma Grade 3 (FLG3): Results From a 398-Case Prospective Randomized Phase III Clinical Trial (NCT00854568)
Authors: Kai Xue, Zhang Qunling, Xiaojian Liu, Junning Cao, Xiaonan Hong, Ye Guo
Journal: Blood (2013)
Factors predicting outcome of G1/2 GEP NET after PRRT with Lu177-octreotate.
Authors: Samer Ezziddin, Mared Attassi, Charlotte Jane Yong-Hing, Amir Sabet, Hojjat Ahmadzadehfar, Winfried Willinek, Frank Gruenwald, Stefan Guhlke, Hans-Juergen Biersack
Journal: Journal of Clinical Oncology (2012)

e14565 Background: Outcome analyses of G1/2 NEN stage IV after peptide receptor radionuclide therapy (PRRT) are still limited, especially with regard to the impact of the Ki-67 index. This study aims to establish predictors of survival. Methods: Retrospective analysis of 74 consecutive GEP NET patients undergoing PRRT with 177Lu-octreotate. Patients had unresectable metastatic disease and a G1/2 grading (33 pancreatic, 41 non-pancreatic GEP- NET), documented morphologic or clinical progression within &lt; 12 months and/or uncontrolled disease. Response (modified SWOG criteria) was correlated with potential impact factors: origin, function, burden, and uptake of tumor, age, Ki-67-index, Karnofsky score, baseline tumor marker levels. Predictors for survival were analyzed with Kaplan-Meier curves (log-rank test) and multivariate analysis (p&lt;0.05). Results: The response rates were 36.5% PR, 17.6% MR, 35.1% SD, and 10.8% PD for the entire cohort, 54.5% PR, 18.2% MR, 18.2% SD, and 9.1% PD for pancreatic NET, and 22.0% PR, 17.1% MR, 48.8% SD, and 12.2% PD for non-pancreatic GEP-NET. The median progression-free (PFS) and overall (OS) survival was 26 months (95% CI, 18.3 - 33.7) and 55 months (95% CI, 48.8–61.2), respectively. The only factor associated with decreased PFS was a Ki-67 index &gt;10% (p=0.002). For OS, besides the Ki-67 index, a Karnofsky score ≤70% and a baseline NSE of &gt;15 ng/ml independently predicted shorter survival (each p&lt;0.005, HR 3.0 - 3.4). Patients with a Ki-67 index &gt;10% still had a median PFS and OS of 19 and 34 months, respectively. Conclusions: This study confirms the favorable outcome of G1/2 NET after PRRT. Independent predictors of survival are the Ki-67 index, the patient‘s performance status and the baseline NSE level. Nevertheless, patients with a Ki-67 &gt;10% may still benefit from PRRT as demonstrated by the long-term outcome.
Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma
Authors: Yi Lisa Hwa, Kristina M Laumann, Betsy R LaPlant, Francis Buadi, David Dingli, Angela Dispenzieri, Morie A Gertz, Ronald S. Go, Suzanne R Hayman, Prashant Kapoor, Shaji K Kumar, Nelson Leung, Yi Lin, John A Lust, Arleigh McCurdy, Joseph Mikhael, Vivek Roy, Stephen Russell, Steven R Zeldenrust, S. Vincent Rajkumar, Martha Q Lacy
Journal: Blood (2013)
IL-23 induced in keratinocytes by endogenous TLR4 ligands polarizes dendritic cells to drive IL-22 responses to skin immunization
Authors: Juhan Yoon, Juan Manuel Leyva-Castillo, Guoxing Wang, Claire Galand, Michiko K. Oyoshi, Lalit Kumar, Sabine Hoff, Rui He, Alexander Chervonsky, Joost J. Oppenheim, Vijay K. Kuchroo, Marcel R.M. van den Brink, Rene De Waal Malefyt, Philippe A. Tessier, Robert Fuhlbrigge, Philip Rosenstiel, Cox Terhorst, George Murphy, Raif S. Geha
Journal: The Journal of Experimental Medicine (2016)

Atopic dermatitis (AD) is a Th2-dominated inflammatory skin disease characterized by epidermal thickening. Serum levels of IL-22, a cytokine known to induce keratinocyte proliferation, are elevated in AD, and Th22 cells infiltrate AD skin lesions. We show that application of antigen to mouse skin subjected to tape stripping, a surrogate for scratching, induces an IL-22 response that drives epidermal hyperplasia and keratinocyte proliferation in a mouse model of skin inflammation that shares many features of AD. DC-derived IL-23 is known to act on CD4+ T cells to induce IL-22 production. However, the mechanisms that drive IL-23 production by skin DCs in response to cutaneous sensitization are not well understood. We demonstrate that IL-23 released by keratinocytes in response to endogenous TLR4 ligands causes skin DCs, which selectively express IL-23R, to up-regulate their endogenous IL-23 production and drive an IL-22 response in naive CD4+ T cells that mediates epidermal thickening. We also show that IL-23 is released in human skin after scratching and polarizes human skin DCs to drive an IL-22 response, supporting the utility of IL-23 and IL-22 blockade in AD.
Presenting Plasma HIV RNA Level and Rate of CD4 T-Cell Decline—Reply
Authors: Benigno Rodriguez, Michael M. Lederman, Ajay K. Sethi, Vinay K. Cheruvu, Ronald J. Bosch, Jeffrey Martin, Steven Deeks
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy
Authors: Katie R. Famous, Kevin Delucchi, Lorraine B. Ware, Kirsten N. Kangelaris, Kathleen D. Liu, B. Taylor Thompson, Carolyn S. Calfee
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

We previously identified two acute respiratory distress syndrome (ARDS) subphenotypes in two separate randomized controlled trials with differential response to positive end-expiratory pressure.To identify these subphenotypes in a third ARDS cohort, to test whether subphenotypes respond differently to fluid management strategy, and to develop a practical model for subphenotype identification.We used latent class analysis of baseline clinical and plasma biomarker data to identify subphenotypes in FACTT (Fluid and Catheter Treatment Trial; n = 1,000). Logistic regression was used to test for an interaction between subphenotype and treatment for mortality. We used stepwise modeling to generate a model for subphenotype identification in FACTT and validated its accuracy in the two cohorts in which we previously identified ARDS subphenotypes.We confirmed that a two-class (two-subphenotype) model best described the study population. Subphenotype 2 was again characterized by higher inflammatory biomarkers and hypotension. Fluid management strategy had significantly different effects on 90-day mortality in the two subphenotypes (P = 0.0039 for interaction); mortality in subphenotype 1 was 26% with fluid-liberal strategy versus 18% with fluid-conservative, whereas mortality in subphenotype 2 was 40% with fluid-liberal strategy versus 50% in fluid-conservative. A three-variable model of IL-8, bicarbonate, and tumor necrosis factor receptor-1 accurately classified the subphenotypes.This analysis confirms the presence of two ARDS subphenotypes that can be accurately identified with a limited number of variables and that responded differently to randomly assigned fluid management. These findings support the presence of ARDS subtypes that may require different treatment approaches.
Modulating Neuronal Competition Dynamics in the Dentate Gyrus to Rejuvenate Aging Memory Circuits
Authors: Kathleen M. McAvoy, Kimberly N. Scobie, Stefan Berger, Craig Russo, Nannan Guo, Pakanat Decharatanachart, Hugo Vega-Ramirez, Sam Miake-Lye, Michael Whalen, Mark Nelson, Matteo Bergami, Dusan Bartsch, Rene Hen, Benedikt Berninger, Amar Sahay
Journal: Neuron (2016)
Infections of Leisure
Authors: Jerry D. Smilack
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The correlation of cone biopsy with findings at radical hysterectomy and the need for adjuvant radiation therapy.
Authors: T. P. Boren, D. L. Richardson, S. M. Kehoe, D. S. Miller
Journal: Journal of Clinical Oncology (2010)

5122 Background: Our objective is to determine if pathologic findings in cone biopsy specimens correlate with residual invasion in radical hysterectomy (RH) specimens and the need for adjuvant radiation therapy (XRT). Methods: We identified 64 patients who underwent a cone biopsy and subsequent RH for the treatment of stage I cervical cancer from 2000-2009. Lymph-vascular space invasion (LVSI), margin status, endocervical curettage (ECC) status, and depth of invasion (< 3 mm or ≥ 3 mm) on the cone biopsy specimens were correlated with the presence of residual invasion in the RH specimens and the need for adjuvant XRT. Univariate comparisons were performed using chi-square analysis. Logistic regression was used to develop predictive models and determine independent predictors of residual invasion and adjuvant XRT. Results: Chi-square analysis revealed that positive deep margin (p < 0.009), ≥ 3 mm of invasion (p < 0.003), and positive endocervical margin (p < 0.001) significantly correlated with the presence of residual disease in the RH specimens. Logistic regression revealed that only ≥ 3 mm of invasion (p < 0.018) correlated independently with residual invasion, while positive ECC (p < 0.052) and positive endocervical margin (p < 0.053) approached significance. Positive ECC (p < 0.001), positive LVSI (p < 0.001), and positive deep margin (p < 0.003) significantly correlated with the need for adjuvant XRT by both chi-square and logistic regression analyses. A model using positive ECC, positive endocervical margin, and ≥ 3 mm of invasion on the cone specimen correlated with residual invasion (r2 = 0.456) and had a positive predictive value of 86.7%. A model using positive LVSI, positive ECC, and positive deep cone margin correlated with the need for adjuvant XRT (r2 = 0.703) and had a positive predictive value of 91.1%. Conclusions: Patients with ≥ 3 mm of invasion, positive ECC, and positive endocervical margin may be at risk for residual invasion in the RH specimen. Patients with positive LVSI, positive ECC, and positive deep cone margin may require adjuvant XRT. These factors should be considered during primary treatment planning in order to avoid the morbidity of multimodal therapy. No significant financial relationships to disclose.
Seasonal variation in incidence of sarcoidosis: a population-based study, 1976–2013
Authors: Patompong Ungprasert, Cynthia S Crowson, Eric L Matteson
Journal: Thorax (2016)

Studies of seasonal patterns of incidence of sarcoidosis may provide a better understanding of potential environmental triggers of the disease. In this study, Olmsted County, Minnesota residents who were diagnosed with sarcoidosis between 1976 and 2013 were identified based on individual medical record review. The seasonal variation of incident sarcoidosis was then calculated. The age-adjusted and sex-adjusted incidence rate of sarcoidosis was lower in autumn (2.0/100 000; 95% CI 1.5 to 2.5) compared with winter (3.2/100 000; 95% CI 2.6 to 3.8), spring (2.8/100 000; 95% CI 2.2 to 3.4) and summer (2.9/100 000; 95% CI 2.2 to 3.5, p=0.024). Subgroup analysis per decade consistently showed lower incidence of sarcoidosis in autumn.
Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATETM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Authors: Jennifer R. Brown, Peter Hillmen, Susan O'Brien, Jaqueline C. Barrientos, Nishitha Reddy, Steven Coutre, Constantine Tam, Stephen Mulligan, Ulrich Jaeger, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Florence Cymbalista, Patrick Thornton, Federico Caligaris-Cappio, Julio Delgado, Marco Montillo, Sven DeVos, Carol Moreno, John Pagel, Jan A. Burger, Devon Chung, Jennifer Lin, Linda Gau, Betty Chang, Jesse McGreivy, Danelle F. James, John C. Byrd
Journal: Blood (2014)
Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer
Authors: Francesco Montorsi, Giorgio Gandaglia, Nicola Fossati, Nazareno Suardi, Cristian Pultrone, Ruben De Groote, Zach Dovey, Paolo Umari, Andrea Gallina, Alberto Briganti, Alexandre Mottrie
Journal: European Urology (2016)
Association of Clinical Factors and Therapeutic Strategies With Improvements in Survival Following Non–ST-Elevation Myocardial Infarction, 2003-2013
Authors: Marlous Hall, Tatendashe B. Dondo, Andrew T. Yan, Shaun G. Goodman, Héctor Bueno, Derek P. Chew, David Brieger, Adam Timmis, Phillip D. Batin, John E. Deanfield, Harry Hemingway, Keith A. A. Fox, Christopher P. Gale
Journal: JAMA (2016)

International studies report a decline in mortality following non-ST-elevation myocardial infarction (NSTEMI). Whether this is due to lower baseline risk or increased utilization of guideline-indicated treatments is unknown.To determine whether changes in characteristics of patients with NSTEMI are associated with improvements in outcomes.Data on patients with NSTEMI in 247 hospitals in England and Wales were obtained from the Myocardial Ischaemia National Audit Project between January 1, 2003, and June 30, 2013 (final follow-up, December 31, 2013).Baseline demographics, clinical risk (GRACE risk score), and pharmacological and invasive coronary treatments.Adjusted all-cause 180-day postdischarge mortality time trends estimated using flexible parametric survival modeling.Among 389 057 patients with NSTEMI (median age, 72.7 years [IQR, 61.7-81.2 years]; 63.1% men), there were 113 586 deaths (29.2%). From 2003-2004 to 2012-2013, proportions with intermediate to high GRACE risk decreased (87.2% vs 82.0%); proportions with lowest risk increased (4.2% vs 7.6%; P= .01 for trend). The prevalence of diabetes, hypertension, cerebrovascular disease, chronic obstructive pulmonary disease, chronic renal failure, previous invasive coronary strategy, and current or ex-smoking status increased (all P < .001). Unadjusted all-cause mortality rates at 180 days decreased from 10.8% to 7.6% (unadjusted hazard ratio [HR], 0.968 [95% CI, 0.966-0.971]; difference in absolute mortality rate per 100 patients [AMR/100], -1.81 [95% CI, -1.95 to -1.67]). These findings were not substantially changed when adjusted additively by baseline GRACE risk score (HR, 0.975 [95% CI, 0.972-0.977]; AMR/100, -0.18 [95% CI, -0.21 to -0.16]), sex and socioeconomic status (HR, 0.975 [95% CI, 0.973-0.978]; difference in AMR/100, -0.24 [95% CI, -0.27 to -0.21]), comorbidities (HR, 0.973 [95% CI, 0.970-0.976]; difference in AMR/100, -0.44 [95% CI, -0.49 to -0.39]), and pharmacological therapies (HR, 0.972 [95% CI, 0.964-0.980]; difference in AMR/100, -0.53 [95% CI, -0.70 to -0.36]). However, the direction of association was reversed after further adjustment for use of an invasive coronary strategy (HR, 1.02 [95% CI, 1.01-1.03]; difference in AMR/100, 0.59 [95% CI, 0.33-0.86]), which was associated with a relative decrease in mortality of 46.1% (95% CI, 38.9%-52.0%).Among patients hospitalized with NSTEMI in England and Wales, improvements in all-cause mortality were observed between 2003 and 2013. This was significantly associated with use of an invasive coronary strategy and not entirely related to a decline in baseline clinical risk or increased use of pharmacological therapies.
Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease
Authors: Dave Singh, Nicolas Roche, David Halpin, Alvar Agusti, Jadwiga A. Wedzicha, Fernando J. Martinez
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Section:ChooseTop of pageAbstract <<Is FEV1 Useful for Guidin...Targeting Treatment towar...Combining Long-Acting Bro...ICS/LABA: Benefit versus ...Initial Pharmacological T...Follow-up Pharmacological...Non-ICS Antiinflammatory ...Personalized Therapy: The...ReferencesCITING ARTICLES
A Prospective Multicenter Phase II Trial of Pentostatin in Adult Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease (cGvHD): A Cancer and Leukemia Group B/Eastern Cooperative Oncology Group Study.
Authors: Sherif Farag, Kouros Owzar, Vera Hars, Hillard M. Lazarus, Edward A. Stadtmauer, Steven M Devine, Koen van Besien, Charles Linker
Journal: Blood (2009)